Triazoloquinazoline derived classical DNA intercalators: Design, synthesis, in silico ADME profile, docking, and antiproliferative evaluations.


Journal

Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167

Informations de publication

Date de publication:
Jun 2022
Historique:
revised: 20 02 2022
received: 21 12 2021
accepted: 22 02 2022
pubmed: 17 3 2022
medline: 3 6 2022
entrez: 16 3 2022
Statut: ppublish

Résumé

Thirteen novel [1,2,4]triazolo[4,3-c]quinazoline derivatives as DNA intercalators were synthesized and their anticancer activities evaluated against HepG2 and HCT-116 cells. A docking study was carried out to explore how the new derivatives bind to active sites of DNA. The docking data were highly interrelated with that of biological testing. The HCT-116 cell line was the most sensitive one to the effect of the new derivatives. Compound 7

Identifiants

pubmed: 35293628
doi: 10.1002/ardp.202100506
doi:

Substances chimiques

Intercalating Agents 0
Quinazolines 0
Triazoles 0
triazoloquinazoline 0
Doxorubicin 80168379AG
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2100506

Informations de copyright

© 2022 Deutsche Pharmazeutische Gesellschaft.

Références

E. Villamon, J. Gonzalez-Fernandez, E. Such, J. V. Cervera, D. Gozalbo, M. Luisa Gil, Cancer Cell Int. 2018, 18, 15.
G. Moarbess, C. Deleuze-Masquefa, V. Bonnard, S. Gayraud-Paniagua, J.-R. Vidal, F. Bressolle, F. Pinguet, P.-A. Bonnet, Bioorg. Med. Chem. 2008, 16, 6601.
D. Kaneko, M. Ninomiya, R. Yoshikawa, Y. Ono, A.D. Sonawane, K. Tanaka, A. Nishina, M. Koketsu, Bioorg. Chem. 2020, 104. 104293. https://doi.org/10.1016/j.bioorg.2020.104293
G. Marzaro, L.D. Via, A. Toninello, A. Guiotto, A. Chilin, Bioorg. Med. Chem. 2011, 19, 1197.
E. B. Skibo, X. Huang, R. Martinez, R. H. Lemus, W. A. Craigo, R. T. Dorr, J. Med. Chem. 2002, 45, 5543.
Z. Ma, Y. Hano, T. Nomura, Y. Chen, Bioorg. Med. Chem. Lett. 2004, 14, 1193.
H. J. Park, Y.-S. Kim, J. S. Kim, E.-J. Lee, Y.-J. Yi, H. J. Hwang, M.-E. Suh, C.-K. Ryu, S. K. Lee, Bioorg. Med. Chem. Lett. 2004, 14, 3385.
B. Oyallon, M. Brachet-Botineau, C. Logé, P. Bonnet, M. Souab, T. Robert, S. Ruchaud, S. Bach, P. Berthelot, F. Gouilleux, Eur. J. Med. Chem. 2018, 154, 101.
A. Garofalo, L. Goossens, B. Baldeyrou, A. Lemoine, S. Ravez, P. Six, M. H. David-Cordonnier, J. P. Bonte, P. Depreux, A. Lansiaux, J. F. Goossens, J. Med. Chem. 2010, 53(22), 8089. https://doi.org/10.1021/jm1009605
K. El-Adl, H. Sakr, M. Nasser, F. M. A. Shoman, Arch. Pharm. 2020, 353, e2000079. https://doi.org/10.1002/ardp.202000079
K. El-Adl, A.-G. A. El-Helby, H. Sakr, S. S. A. El-Hddad, Arch. Pharm. 2020, 353, e2000068. https://doi.org/10.1002/ardp.202000068
K. El-Adl, A.-G. A. El-Helby, H. Sakr, I. H. Eissa, S. S. A. El-Hddad, F. M. I. A. Shoman, Bioorg. Chem. 2020, 102, 104059.
A. M. Sayed, F. A. Taher, M. R. K. Abdel-Samad, M. S. A. El-Gaby, K. El-Adl, N. M. Saleh, Bioorg. Chem. 2021, 108, 104669. https://doi.org/10.1016/j.bioorg.2021.104669
M. H. El-Shershaby, A. Ghiaty, A. H. Bayoumi, H. E. A. Ahmed, M. S. El-Zoghbi, K. El-Adl, H. S. Abulkhair, New J. Chem. 2021, 45, 11136. https://doi.org/10.1039/D1NJ00710F
A. A. El-Helby, H. Sakr, R. Ayyad, K. El-Adl, M. M. Ali, F. Khedr, Anti-Cancer Agents Med. Chem. 2018, 18(8), 1184.
K. El-Adl, A. A. El-Helby, H. Sakr, A. Elwan, Bioorg. Chem. 2020, 105, 104399. https://doi.org/10.1016/j.bioorg.2020.104399
K. El-Adl, A. A. El-Helby, H. Sakr, A. Elwan, New J. Chem. 2021, 45, 881. https://doi.org/10.1039/D0NJ02990D
N. E. A. Abd El-Sattar, K. El-Adl, M. A. El-Hashash, S. A. Salama, M. M. Elhady, Bioorg. Chem. 2021, 115, 105186. https://doi.org/10.1016/j.bioorg.2021.105186
K. El-Adl, M. K. Ibrahim, M. S. I. Alesawy, I. H. Eissa, Bioorg. Med. Chem. 2021, 30, 115958. https://doi.org/10.1016/j.bmc.2020.115958
M. F. Braña, M. Cacho, A. Gradillas, B. de Pascual-Teresa, A. Ramos, Curr. Pharm. Des. 2001, 7(17), 1745. https://doi.org/10.2174/1381612013397113
S. A. Bailey, D. E. Graves, R. Rill, Biochemistry 1994, 33, 11493.
D. E. Graves, L. M. Velea, Curr. Org. Chem. 2000, 4, 915.
M. K. Goftar, N. M. Kor, Z. M. Kor, Int. J. Adv. Biol. Biomed. Res. 2014, 2(3), 811.
L. Strekowski, B. Wilson, Mutat. Res. 2007, 623(1-2), 3.
A. Paul, S. Bhattacharya, Curr. Sci. 2012, 102, 212.
A. A. El-Helby, R. Ayyad, H. Sakr, K. El-Adl, M. M. Ali, F. Khedr, Arch. Pharm.2017, 350(12), 1700240.
F. Gago, Methods 1998, 14, 277.
C. Avendano, J. Menéndez, DNA Intercalators and Topoisomerase Inhibitors, Medicinal Chemistry of Anticancer Drugs, 2nd ed., Elsevier, 2008, p. 199.
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni, Pharmacol. Rev. 2004, 56(2), 185. https://doi.org/10.1124/pr.56.2.6
J. Gallego, A. R. Ortiz, B. de Pascual-Teresa, F. Gago, J. Comput.-Aided. Mol. Des. 1997, 11, 114.
A. Soni, P. Khurana, T. Singh, B. Jayaram, Bioinformatics 2017, 33(10), 1488. https://doi.org/10.1093/bioinformatics/btx006
S. Takenaka, M. Takagi, Bull. Chem. Soc. Jpn. 1999, 72, 327.
L. F. Liu, Annu. Rev. Biochem. 1989, 58, 351.
A. Chilin, G. Marzaro, C. Marzano, L. Dalla Via, M. G. Ferlin, G. Pastorini, A. Guiotto, Bioorg. Med. Chem. 2009, 17, 523.
T. D. Shenkenberg, D.D. Von Hoff, Ann. Intern. Med. 1986, 105, 67.
G. Lipunova, E. Nosova, G. Mokrushina, L. Sidorova, V. Charushin, Pharm. Chem. J. 2000, 34, 19.
C. C. Wu, Y. C. Li, Y. R. Wang, T. K. Li, N. L. Chan, Nucleic Acids Res. 2013, 41(22), 10630. https://doi.org/10.1093/nar/gkt828
T. Mosmann, J. Immunol. Methods 1983, 65(1-2), 55.
D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, M. R. Boyd, Cancer Res. 1988, 48(17), 4827.
F. M. Freimoser, C. A. Jakob, M. Aebi, U. Tuor, Appl. Environ. Microbiol. 1999, 65(8), 3727.
N. S. Burres, A. Frigo, R. R. Rasmussen, J. B. McAlpine, J. Nat. Prod. 1992, 55, 1582.
C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Deliv. Rev. 1997, 23, 3. https://doi.org/10.1016/S0169-409X(96)00423-1
D. E. V. Pires, T. L. Blundell, D. B. Ascher, J. Med. Chem. 2015, 58, 4066. https://doi.org/10.1021/acs.jmedchem.5b00104
A. Beig, R. Agbaria, A. Dahan, PLoS One 2013, 8, e68237. https://doi.org/10.1371/journal.pone.0068237

Auteurs

Khaled El-Adl (K)

Pharmaceutical Medicinal Chemistry and Drug Design Department, Al-Azhar University, Cairo, Egypt.
Pharmaceutical Chemistry Department, Heliopolis University for Sustainable Development, Cairo, Egypt.

Mohamed-Kamal Ibrahim (MK)

Pharmaceutical Medicinal Chemistry and Drug Design Department, Al-Azhar University, Cairo, Egypt.

Mohamed S Alesawy (MS)

Pharmaceutical Medicinal Chemistry and Drug Design Department, Al-Azhar University, Cairo, Egypt.

Ibrahim H Eissa (IH)

Pharmaceutical Medicinal Chemistry and Drug Design Department, Al-Azhar University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH